Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
41.11 USD | +3.21% | -0.92% | -31.96% |
05-31 | Piper Sandler Starts Apellis Pharmaceuticals With Neutral Rating, $46 Price Target | MT |
05-24 | Apellis Pharmaceuticals, Sobi Say Pegcetacoplan Reduces Post-Transplant Kidney Diseases | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-31.96% | 4.83B | |
-0.28% | 90.59B | |
-0.92% | 38.99B | |
-10.00% | 34.09B | |
+64.26% | 26.38B | |
-18.92% | 15.02B | |
-6.72% | 13.17B | |
-10.69% | 11.88B | |
-47.31% | 10.65B | |
+7.64% | 9.25B |
- Stock Market
- Equities
- APLS Stock
- News Apellis Pharmaceuticals, Inc.
- Apellis Pharmaceuticals Enters Into Senior Secured Credit Facility With Sixth Street